跳至主要内容
临床试验/NCT01757483
NCT01757483已完成不适用

Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada

AstraZeneca1 个研究点 分布在 1 个国家目标入组 244 人开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
244
试验地点
1
主要终点
KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)

研究概览

简要总结

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

详细描述

Effectiveness of risk minimisation interventions for ticagrelor in Canada

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • N/A (All prescribers will be contacted for participation)

排除标准

  • Participation in a previous wave of the survey.

结局指标

主要结局

KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)

时间窗: 2 months

次要结局

  • KAU Questionnaire: Practice characteristics(2 months)
  • KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns(2 months)
  • KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.(2 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验